Livio Trusolino
Molecular Biology · 2002–2019
A researcher in the Science corpus: 9 papers; trusts 3 researchers and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 93 citations into it; #7,117 of 17,773 by trust here, #9,136 by citations
- Cancer Research — 63 citations into it
- Cell Biology — 16 citations into it
Whom Livio Trusolino trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- Peter Carmeliet
- Liqun Luo
- P. Comoglio
- Gerhard Christofori
- G. Evan
- R. Weinberg
- Raghu Kalluri
- Jing Yang
- Jayanta Debnath
- C. Blanpain
Who trusts Livio Trusolino overall
Papers from Livio Trusolino's perspective
Ordered by how strongly the researchers Livio Trusolino trusts endorse each paper. Same corpus, a different order for every researcher.
- Met, metastasis, motility and more (Nature reviews. Molecular cell biology)
- The basics of epithelial-mesenchymal transition. (Journal of Clinical Investigation)
- Scatter-factor and semaphorin receptors: cell signalling for invasive growth (Nature Reviews. Cancer)
- Epithelial-mesenchymal transitions in development and disease. (Cell)
- Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. (Developmental Cell)
- Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. (Proceedings of the National Academy of Sciences of the United States of America)
- Proliferation, cell cycle and apoptosis in cancer (Nature)
- Mechanisms of angiogenesis and arteriogenesis (Nature Medicine)
- RHO GTPASES in neuronal morphogenesis (Nature Reviews Neuroscience)
- Comparative lesion sequencing provides insights into tumor evolution (Proceedings of the National Academy of Sciences of the United States of America)
Their papers
- Scatter-factor and semaphorin receptors: cell signalling for invasive growth (2002) — 786 citations
- Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens (2019) — 1,126 citations
- Drug development of MET inhibitors: targeting oncogene addiction and expedience (2008) — 845 citations
- MET signalling: principles and functions in development, organ regeneration and cancer (2010) — 1,225 citations
- Interrogating open issues in cancer precision medicine with patient-derived xenografts (2017) — 601 citations
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. (2016) — 867 citations
- Patient Derived Xenograft Models: An Emerging Platform for Translational Cancer Research (2014) — 1,525 citations
- Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer (2013) — 633 citations
- A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. (2011) — 894 citations